Zusammenfassung
Osteoporotische Knochenbrüche sind eine häufige Ursache von Einbußen an Selbständigkeit und Lebensqualität im Alter. Der Erhalt von Muskulatur und Koordination, die tägliche Zufuhr von 1000 mg Kalzium, eine ausreichende Versorgung mit Vitamin D und ein umsichtiger Umgang mit Sturz- bzw. Osteoporose-fördernden Medikamenten sind die wichtigsten Basismaßnahmen zur Frakturvermeidung. Ab einem 10-Jahres-Frakturrisiko von 30% für proximale Femurfrakturen und Wirbelkörperfrakturen empfiehlt die Leitlinie des Dachverbands Osteologie eine Langzeittherapie mit spezifischen Osteoporosemedikamenten.
Abstract
Osteoporotic fractures are a frequent cause of disability and loss of quality of life in old age. Maintaining muscle function and balance, a daily calcium intake of 1000 mg, sufficient vitamin D and prudent use of drugs associated with falls and osteoporosis are key components to fracture prevention. The German guideline recommends that a specific long-term osteoporosis medication be initiated in individuals with a 30% 10-year risk for hip fractures and vertebral fractures.
Literatur
Consensus Development Conference (1993) Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 94:646–656
Hiligsmann M, Ethgen O, Richy F et al (2008) Utility values associated with osteoporotic fracture: A systematic review of the literature. Calcif Tissue Int 82:288–292
Kanis JA, Johnell O, De Laet C et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375–382
Blake GM, Fogelman I (2007) Role of dual-energy x-ray absorptiometry in the diagnosis and treatment of osteoporosis. J Clin Densitom 10:102–110
Tervo T, Nordström P, Neovius M et al (2008) Constant adaptation of bone to current physical activity level in men: A 12-year longitudinal study. J Clin Endocrinol Metab 93:4873–4879
Steingrimsdottir L, Gunnarsson O, Indridason OS et al (2005) Relationship between serum parathyroid hormone levels, vitamin D sufficiency and calcium intake. JAMA 294:2336–2341
Bolland MJ, Barber PA, Doughty RN et al (2008) Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ 336:262–266
Holick MF, Chen TC (2008) Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr 87:1080S–1086S
Bauer DC, Ettinger B, Nevitt MC et al (2001) Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 134:561–568
Orstavik RE, Haugeberg G, Mowinckel P et al (2004) Vertebral deformities in rheumatoid arthritis: a comparison with population-based controls. Arch Intern Med 164(4):420–425
Kanis JA, Johansson H, Oden A et al (2004) A metaanalysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19(6):893–899
Staa TP van, Geusens P, Bijlsma JW et al (2006) Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 54(10):3104–3112
Bianchi G, Sambrook P (2008) Oral nitrogen-containing bisphosphonates: a systematic review of randomized clinical trials and vertebral fractures. Curr Med Res Opin 24:2669–2677
DVO-Leitlinie 2009 zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Erwachsenen. Osteologie 18:304–328, http://www.dv-osteologie.org/dvo_leitlinien/dvo-leitlinie-2009
McCloskey EV, Johansson H, Oden A et al (2008) Ten-year fracture probability identifies women who will benefit from clodronate therapy-additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 20:811–817
Saag KG, Shane E, Boonen S et al (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028–2039
Seeman E (2007) Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy? Bone 41:308–317
Curtis JR, Westfall AO, Cheng H et al (2008) Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int 19:1613–1620
Gallagher A, Rietbrock S, Olson M et al (2008) Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 23:1569–1575
Ito Z, Harada A, Matsui Y et al (2006) Can you diagnose for vertebral fracture correctly by plain X-ray? Osteoporos Int 17:1584–1591
Pfeilschifter J (2007) Schmerztherapie bei Osteoporose. Allgemeinarzt 19:32–37
Smith MR, Egerdie B, Hernández Toriz N et al (2009) Denosumab halt prostate cancer study group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361(8):745–755
Cummings SR, San Martin J, McClung MR et al (2009) Freedom trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Braun, J., Pfeilschifter, J. Leitliniengerechte Diagnostik und Therapie der Osteoporose 2010. Z. Rheumatol. 69, 327–339 (2010). https://doi.org/10.1007/s00393-010-0623-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00393-010-0623-3